AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15713524
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/m2 on days 1, 8, 15, every 28 days (arm Q4W)
Trial: 15713524
Drug: Gemcitabine 1125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1125 mg/m2 on days 1 and 8, every 21 days (arm Q3W)
Trial: 9794735
Drug: Lacidipine (calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine (calcium antagonist)
Trial: 9097789
Drug: PRP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP treatment after TC‐INV/ANV developed
Trial: 9097789
Drug: PRP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP treatment after TC‐INV/ANV developed (previously treated eyes)
Trial: 31512365
Drug: metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin plus lifestyle intervention (LSI)
Trial: 31512365
Drug: metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin 850 mg once daily for the first 2 weeks, then twice daily thereafter
Trial: 29362047
Drug: Dexmedetomidine (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.2 mcg/kg/hour)
Trial: 27978912
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment using periodontal endoscope
Trial: 27978912
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment method (control group)
Trial: 12011683
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with cytokine adjuvants, peeling of the internal limiting membrane, vital staining with indocyanine green dye, variations in postoperative face-down positioning
Trial: 9642895
Drug: Both forms
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both forms of therapy
Trial: 1217691
Drug: No antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antithrombotic medications (Control)
Trial: 30892806
Drug: Digitoxin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitoxin (target serum concentration 8-18 ng/mL)
Trial: 28224950
Drug: Injection-site splinting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection-site splinting (experimental group)
Trial: 28224950
Drug: No injection-site
RxNorm normalized name: No Dolo Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No injection-site splinting (control group)
Trial: 26027223
Drug: Reamberin 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reamberin 1.5% (succinate‐containing infusion solution)
Trial: 21422859
Drug: Cefazolin 2
RxNorm normalized name: cefazolin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin 2 g administered 30-60 minutes before skin incision
Trial: 15127162
Drug: Thêta-Cream
RxNorm normalized name: menthol / methyl salicylate Topical Cream [Thera-Gesic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thêta-Cream
Trial: 15127162
Drug: Bepanthol lotion
RxNorm normalized name: Bepantol
DrugBank: Dexpanthenol (DB09357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bepanthol lotion
Trial: 9915106
Drug: Basal (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal (no drug administration)
Trial: 30613020
Drug: Propofol sedation
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol sedation (loading dose of 0.6 mg·kg‐1·h‐1 followed by maintenance dose of 3 mg·kg‐1·h‐1)
Trial: 22820601
Drug: RhTPO (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RhTPO (1.0 µg/kg) administered subcutaneously daily for 7 days starting 3 days before the second chemotherapy cycle (Group A)
Trial: 22820601
Drug: RhTPO (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RhTPO (1.0 µg/kg) administered daily for 7 days starting 6-24 hours after the second chemotherapy cycle (Group B)
Trial: 22820601
Drug: Control cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control cycle (no RhTPO administered during the first chemotherapy cycle)
Trial: 12930046
Drug: Self‐administered Client
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐administered Client Perceptions of Coordination Questionnaire
Trial: 8241701
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 therapy
Trial: 8241701
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients without coenzyme Q10 therapy)
Trial: 4089312
Drug: Acipimox (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (3 X 250 mg/day)
Trial: 31100534
Drug: GIP (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIP (200 μg)
Trial: 31100534
Drug: GLP-2 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-2 (800 μg)
Trial: 31100534
Drug: GIP(3-30)NH2 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIP(3-30)NH2 (800 pmol/kg/min) + GLP-2 (800 μg)
Trial: 25383369
Drug: Electromyography-guided botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromyography-guided botulinum toxin injection
Trial: 25383369
Drug: Fiberscopy-guided botulinum
RxNorm normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fiberscopy-guided botulinum toxin injection
Trial: 22490651
Drug: Mifepristone (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (various doses)
Trial: 22490651
Drug: Mifepristone (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (high dose)
Trial: 17906182
Drug: Walnut-supplemented diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut-supplemented diet (mean 35 grams daily, 12% total energy)
Trial: 12188483
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of steroid (20 mg of triamcinolone with lignocaine)
Trial: 12188483
Drug: Extracorporeal shock-wave
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock-wave therapy (2000 shock waves in three sessions at weekly intervals)
Trial: 10457271
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg daily for 1 year)
Trial: 19284933
Drug: Vilazodone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilazodone (10 mg to 40 mg once a day for 8 weeks)
Trial: 8392261
Drug: Essential fatty
RxNorm normalized name: essential fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Essential fatty acids treatment
Trial: 28623089
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric bupivacaine 0.5% (12.6mg) with 15μg fentanyl and 75μg morphine
Trial: 28623089
Drug: Intrathecal hyperbaric
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric bupivacaine 0.5% (6.0mg) with 15μg fentanyl and 75μg morphine
Trial: 28623089
Drug: Increasing doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of bupivacaine
Trial: 15566506
Drug: Peginterferon alpha-2b
RxNorm normalized name: ROPEGINTERFERON ALPHA-2B-NJFT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon alpha-2b plus ribavirin (100 microg once weekly and 800 mg/day orally)
Trial: 15566506
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b plus ribavirin (3 million units thrice weekly and 800 mg/day)
Trial: 3336176
Drug: Topical tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin applied to forearm
Trial: 3336176
Drug: Topical tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tretinoin applied to face
Trial: 3336176
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream applied to forearm
Trial: 3336176
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream applied to face
Trial: 26665460
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg by muscle injection 30 min before the operation followed by saline every 24 h for 48 h (Group A)
Trial: 26665460
Drug: Parecoxib 40
RxNorm normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib 40 mg by muscle injection 30 min before the operation followed by 40 mg every 24 h for 48 h (Group B)
Trial: 23905652
Drug: Black pepper
RxNorm normalized name: Black Pepper
DrugBank: Black pepper (DB10557)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black pepper (2.0 g)
Trial: 23905652
Drug: Rosemary (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosemary (1.7 g)
Trial: 23905652
Drug: Placebo (3.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3.1 g rice flour)
Trial: 21692235
Drug: Lornoxicam (LNX)
RxNorm normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam (LNX) 8 mg
Trial: 21692235
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac potassium (DP) 50 mg
Trial: 14727000
Drug: Fluoxetine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 30 mg daily
Trial: 11395188
Drug: Naltrexone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (25 mg/day for 3 days)
Trial: 8425445
Drug: Lactose challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose challenge (2 g/kg) in lactose-intolerant children
Trial: 8425445
Drug: Lactose challenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose challenge (2 g/kg) in normal children
Trial: 2906174
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg four times daily plus placebo
Trial: 2906174
Drug: Nifedipine 10
RxNorm normalized name: nifedipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 10 mg four times daily plus famotidine 40 mg once daily
Trial: 21937568
Drug: Oxycodone/naloxone prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone/naloxone prolonged-release tablets (OXN PR)
Trial: 21937568
Drug: Oxycodone prolonged-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone prolonged-release tablets (OxyPR)
Trial: 16054413
Drug: GH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH treatment (subcutaneous injections of GH 0.03 IU/kg/daily) for 5 days
Trial: 16054413
Drug: IGF-I treatment
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IGF-I treatment (continuous subcutaneous infusion of 5 microg/kg/h recombinant IGF-I) for 5 days
Trial: 9522112
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blocker therapy
Trial: 7877347
Drug: Carbimazole (decreasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole (decreasing doses)
Trial: 7877347
Drug: Carbimazole (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole (high doses) plus Levothyroxine
Trial: 1688617
Drug: MACOP-B chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MACOP-B chemotherapy regimen (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin)
Trial: 1688617
Drug: MACOP-B chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MACOP-B chemotherapy regimen
Trial: 31297962
Drug: ICIs plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICIs plus chemotherapy
Trial: 22268699
Drug: Fractionated CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractionated CO2 laser therapy
Trial: 15726120
Drug: EoP (Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EoP (Cisplatin plus oral etoposide); etoposide 50 mg p.o. twice a day for 7 days, cisplatin 70 mg/m² i.v. on day 1, repeated every 3 weeks.
Trial: 15726120
Drug: Paclitaxel; 175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel; 175 mg/m² i.v. on day 1, repeated every 3 weeks.
Trial: 12799102
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) with conjugated estrogen and medroxyprogesterone for 3 months
Trial: 8888304
Drug: Upright biological-motion
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upright biological-motion displays
Trial: 8888304
Drug: Inverted biological-motion
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inverted biological-motion displays
Trial: 27890050
Drug: Interprofessional medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interprofessional medication management
Trial: 20672451
Drug: Single-dose nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose nevirapine + zidovudine + lamivudine
Trial: 12028899
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) 4.5 MU/daily for 24 weeks, followed by 4.5 MU/48 hours for a further 24 weeks (if ALT was normal)
Trial: 6966882
Drug: terodiline 12.5
RxNorm normalized name: terodiline 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terodiline 12.5 mg twice daily
Trial: 30362650
Drug: CAD/CAM-processed implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAD/CAM-processed implant crowns
Trial: 24531123
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g dark chocolate
Trial: 24531123
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g white chocolate (control)
Trial: 24603643
Drug: NEPA (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEPA (300 mg netupitant + 0.50 mg palonosetron)
Trial: 22871128
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate supplementation (600 mg·kg(‐1); CIT group)
Trial: 18292704
Drug: Laboratory research
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laboratory research and treatment trials for marijuana dependence; specific interventions not detailed.
Trial: 16801747
Drug: Local guidelines,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local guidelines, de-escalation, rotation and association therapies
Trial: 12546525
Drug: 5-FU 400
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 400 mg/m2 (group A)
Trial: 12546525
Drug: 5-FU 500
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 500 mg/m2 (group B)
Trial: 12546525
Drug: 5-FU 600
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 600 mg/m2 (group C)
Trial: 10643517
Drug: Tamoxifen or
RxNorm normalized name: tamoxifen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen or interferon therapy
Trial: 10643517
Drug: Extracorporal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporal shock wave therapy
Trial: 2291867
Drug: Captopril (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (12.5, 25, and 50 mg)
Trial: 6114712
Drug: Combined H1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined H1 (hydroxyzine hydrochloride) and H2 (cimetidine) antihistamines
Trial: 6114712
Drug: H1 antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 antihistamines alone
Trial: 31199705
Drug: Huoxin formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Huoxin formula (13.5 g granules dissolved in 150 mL warm water, twice a day)
Trial: 31199705
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (only cardiovascular drugs)
Trial: 28029540
Drug: Booster dose
RxNorm normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster dose of combined Haemophilus influenzae type b and MenC‐tetanus toxoid vaccine (Hib‐MenC‐TT)
Trial: 28029540
Drug: One MenC‐TT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One MenC‐TT dose
Trial: 28029540
Drug: Two MenC‐CRM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two MenC‐CRM vaccine doses
Trial: 24929023
Drug: H2-saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2-saline infusion (1 ppm H2-dissolved saline)
Trial: 24929023
Drug: Placebo-saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-saline infusion
Trial: 22344504
Drug: Enhanced eGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced eGFR laboratory prompt (subgroup with eGFR <30 ml/min per 1.73 m²)
Trial: 22344504
Drug: Standard eGFR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard eGFR laboratory prompt (subgroup with eGFR <30 ml/min per 1.73 m²)
Trial: 19546122
Drug: Silicone bulking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone bulking agent injection
Trial: 17587724
Drug: Azosemide (long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azosemide (long-acting diuretic)
Trial: 11305519
Drug: Glibenclamide (5-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5-mg tablet) plus glucose (10% infusion at 62.5 ml/h for 12 h)
Trial: 9356038
Drug: Combined infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined infusion of insulin and norepinephrine (NE)
Trial: 1000195
Drug: Intravenous dextran
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dextran 70 and pneumatic leggings
Trial: 26927446
Drug: CAP/BEV/VIN (capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP/BEV/VIN (capecitabine at 1000 mg/m² twice daily for days 1-14, q3w + bevacizumab at 15 mg/kg on day 1, q3w + vinorelbine at 25 mg/m² on days 1 + 8, q3w)
Trial: 26927446
Drug: CAP/BEV (capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAP/BEV (capecitabine at 1000 mg/m² twice daily for days 1-14, q3w + bevacizumab at 15 mg/kg on day 1, q3w)
Trial: 19602719
Drug: Sitagliptin 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 800 mg
Trial: 17251808
Drug: 0.32% hypromellose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.32% hypromellose solution
Trial: 14734438
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (combination regimens)
Trial: 12076220
Drug: NPPV by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPPV by face mask plus standard medical therapy (n = 39)
Trial: 12076220
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy alone (n = 42)
Trial: 9872357
Drug: High CDT
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High CDT group (CDT >20 U/l on admission)
Trial: 9872357
Drug: Low CDT
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low CDT group (CDT <= 20 U/l on admission)
Trial: 24129613
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist co-treatment started on CD 2
Trial: 24129613
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist co-treatment started on CD 6
Trial: 21327806
Drug: i.v. ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. ketamine 0.5 mg/kg
Trial: 21327806
Drug: i.v. saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. saline 5 ml (control saline group)
Trial: 12506278
Drug: Levodopa-carbidopa (1.86
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa-carbidopa (1.86 mg/kg/day, 4:1 ratio) with occlusion therapy
Trial: 12506278
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with occlusion therapy
Trial: 7897117
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue‐type plasminogen activator (rt‐PA) (100 mg over 3 h)
Trial: 2766722
Drug: Norethindrone-1mg/mestranol-50 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethindrone-1mg/mestranol-50 micrograms formulations (1 + 50)
Trial: 2766722
Drug: Norethindrone-1mg/ethinyl estradiol-35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethindrone-1mg/ethinyl estradiol-35 micrograms formulations (1 + 35)
Trial: 783197
Drug: ouabain (0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ouabain (0.015 mg/kg body weight)